Skip to content

Early enteral supply of Intestamin® in severe sepsis and its influence on organ dysfunction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN27438588
Enrollment
52
Registered
2006-06-02
Start date
2006-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis Infections and Infestations Sepsis

Interventions

Intestamin® versus placebo

Sponsors

Fresenius Kabi Deutschland GmbH (Germany)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Major entry criteria (suspected or proven infection, presence of a systemic response to the infection within the 48-hour period immediately preceding enrolment into the study, have or have had one or more sepsis-induced organ failures within the 48-hour period immediately preceding enrolment into the study). 1. Age =18 years 2. Acute Physiology and Chronic Health Evaluation II (APACHE II) score =10 3. Precipitating injury (surgery, trauma, hypovolemia, episode of infection or sepsis) occurred within the last 48 hours before intensive care unit (ICU) entry 4. Expected length of stay (LOS) in the ICU >3 days 5. Indication for enteral nutrition for 5-10 days 6. Start of nutritional therapy with Intestamin or control supplement within 24 hours after inclusion criteria are fulfilled

Exclusion criteria

Exclusion criteria: 1. Age 130 kg (estimated) 3. Pregnant and lactating women, women of child-bearing age. Pregnancy in women of child-bearing age should be ruled out with a pregnancy test. 4. Gastrointestinal obstructions, high output enterocutaneous fistulae 5. Severe diarrhoea unresponsive to codeine or loperamide 6. Biopsy proven cirrhosis and documented portal hypertension; episodes of past upper gastrointestinal bleeding attributed to portal hypertension; prior episodes of hepatic failure, encephalopathy or coma 7. Human immunodeficiency virus (HIV)-positive patients with an aquired immune deficiency syndrome (AIDS)-defining process, such as Pneumocystis carnii pneumonia, Kaposi?s sarcoma, progressive multifocal leukoncephalopathy (PML), Mycobacterium avium disease, Epstein-Barr virus (EBV) infection, or lymphoma, or a known CD4 count <200 cells/µl 8. Simultaneous participation in another clinical study

Design outcomes

Primary

MeasureTime frame
Organ dysfunction assessed by daily total SOFA score and by the delta daily total SOFA score (significant reduction). Variables for organ dysfunction (worst parameter per day): 1. Pulmonary: pO2/FiO2 2. Cardiovascular: hypotension 3. Renal: creatinine 4. Hepatic: bilirubin 5. Coagulation: thrombocytes 6. Central nervous system (CNS): Glasgow coma score

Secondary

MeasureTime frame
1. Mortality (28-day, ICU and hospital, six-months) 2. Infectious complications (e.g. pneumonia, wound infection, abscesses) 3. APACHE II 4. Organ failure-free days 5. LOS in ICU 6. LOS in hospital (intervention until discharge) 7. Duration of antibiotic treatment (antibiotics days) 8. Duration of ventilation (ventilator days) 9. Duration of renal support

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026